BR112013019643A2 - inibidores de alk, uso e composição farmacêutica compreendendo os mesmos - Google Patents

inibidores de alk, uso e composição farmacêutica compreendendo os mesmos

Info

Publication number
BR112013019643A2
BR112013019643A2 BR112013019643A BR112013019643A BR112013019643A2 BR 112013019643 A2 BR112013019643 A2 BR 112013019643A2 BR 112013019643 A BR112013019643 A BR 112013019643A BR 112013019643 A BR112013019643 A BR 112013019643A BR 112013019643 A2 BR112013019643 A2 BR 112013019643A2
Authority
BR
Brazil
Prior art keywords
same
pharmaceutical composition
alk inhibitors
alk
inhibitors
Prior art date
Application number
BR112013019643A
Other languages
English (en)
Other versions
BR112013019643B1 (pt
Inventor
Fangxian Sun
Jennifer L Harris
Nanxin Li
Peter Mcnamara
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45582065&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013019643(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of BR112013019643A2 publication Critical patent/BR112013019643A2/pt
Publication of BR112013019643B1 publication Critical patent/BR112013019643B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

resumo patente de invenção: "métodos de usar inibidores de álcali". a invenção provê métodos para usar compostos de fórmula (i) (i) para tratar uma condição mediada eml4-alk+ tal como câncer de pulmão de célula não pequena eml4-alk+, e opcionalmente resistente a crizotinib; em que r1, r2, r3, r4, r5 e r6 são como definidos acima.
BR112013019643-2A 2011-02-02 2012-02-02 Uso de inibidores de álcali BR112013019643B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438878P 2011-02-02 2011-02-02
US61/438,878 2011-02-02
PCT/US2012/023669 WO2012106540A1 (en) 2011-02-02 2012-02-02 Methods of using alk inhibitors

Publications (2)

Publication Number Publication Date
BR112013019643A2 true BR112013019643A2 (pt) 2016-10-04
BR112013019643B1 BR112013019643B1 (pt) 2022-04-19

Family

ID=45582065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013019643-2A BR112013019643B1 (pt) 2011-02-02 2012-02-02 Uso de inibidores de álcali

Country Status (22)

Country Link
US (1) US8703787B2 (pt)
EP (1) EP2670401B1 (pt)
JP (1) JP5837095B2 (pt)
KR (1) KR101521861B1 (pt)
CN (1) CN103458881B (pt)
AU (1) AU2012212142B2 (pt)
BR (1) BR112013019643B1 (pt)
CA (1) CA2824092C (pt)
CY (1) CY1116662T1 (pt)
DK (1) DK2670401T3 (pt)
EA (1) EA023404B1 (pt)
ES (1) ES2543567T3 (pt)
HR (1) HRP20150946T1 (pt)
HU (1) HUE025395T2 (pt)
ME (1) ME02200B (pt)
MX (1) MX2013008791A (pt)
PL (1) PL2670401T3 (pt)
PT (1) PT2670401E (pt)
RS (1) RS54189B1 (pt)
SI (1) SI2670401T1 (pt)
SM (1) SMT201500300B (pt)
WO (1) WO2012106540A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102156398B1 (ko) 2012-11-06 2020-09-15 상하이 포천 파마슈티컬 씨오 엘티디 Ａｌｋ 키나아제 억제제
AU2013341271A1 (en) * 2012-11-07 2015-05-14 Novartis Ag Combination therapy
CN104109149B (zh) * 2013-04-22 2018-09-28 苏州泽璟生物制药有限公司 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物
ITMI20131124A1 (it) 2013-07-04 2015-01-05 Univ Milano Bicocca 2-acilamminotiazoli per il trattamento del cancro
RU2656591C2 (ru) * 2013-07-11 2018-06-06 Бетта Фармасьютикалз Ко., Лтд Модуляторы протеин-тирозинкиназы и способы их применения
CA2922684A1 (en) * 2013-08-28 2015-03-05 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
CN104672214B (zh) * 2013-12-03 2019-04-12 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
RU2016129953A (ru) * 2013-12-23 2018-01-30 Новартис Аг Фармацевтические комбинации
KR101656382B1 (ko) * 2014-02-28 2016-09-09 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
CN104876914B (zh) * 2014-02-28 2017-04-19 山东轩竹医药科技有限公司 嘧啶衍生物类间变性淋巴瘤激酶抑制剂
CA2952787A1 (en) * 2014-06-17 2015-12-23 Korea Research Institute Of Chemical Technology Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient
CN105524045B (zh) * 2014-10-22 2020-04-10 山东轩竹医药科技有限公司 四环类间变性淋巴瘤激酶抑制剂
CN106146525B (zh) * 2015-04-10 2018-11-02 山东轩竹医药科技有限公司 三并环类间变性淋巴瘤激酶抑制剂
US10259816B2 (en) 2015-04-24 2019-04-16 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
CN106699743B (zh) 2015-11-05 2020-06-12 湖北生物医药产业技术研究院有限公司 嘧啶类衍生物及其用途
CN106220608B (zh) * 2016-07-25 2018-11-27 安润医药科技（苏州）有限公司 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
CN107698603B (zh) * 2016-08-09 2022-04-08 南京红云生物科技有限公司 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用
CN115043821A (zh) * 2016-08-29 2022-09-13 密歇根大学董事会 作为alk抑制剂的氨基嘧啶
CN111484484B (zh) * 2020-04-13 2021-11-23 沈阳药科大学 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
BR122019017579B8 (pt) * 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
ES2533575T3 (es) 2006-07-10 2015-04-13 Goji Limited Método y sistema para calentamiento con microondas de multifrecuencia
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP2091918B1 (en) * 2006-12-08 2014-08-27 Irm Llc Compounds and compositions as protein kinase inhibitors
RS53588B1 (en) * 2006-12-08 2015-02-27 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
EA018282B1 (ru) * 2008-04-07 2013-06-28 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы

Also Published As

Publication number Publication date
US20130296357A1 (en) 2013-11-07
JP5837095B2 (ja) 2015-12-24
PL2670401T3 (pl) 2015-11-30
EA201391114A1 (ru) 2013-12-30
BR112013019643B1 (pt) 2022-04-19
CN103458881B (zh) 2015-08-12
EP2670401B1 (en) 2015-06-10
US8703787B2 (en) 2014-04-22
SI2670401T1 (sl) 2015-10-30
CN103458881A (zh) 2013-12-18
WO2012106540A1 (en) 2012-08-09
MX2013008791A (es) 2013-10-07
HUE025395T2 (en) 2016-02-29
DK2670401T3 (en) 2015-09-07
ME02200B (me) 2016-02-20
RS54189B1 (en) 2015-12-31
AU2012212142B2 (en) 2015-09-24
CY1116662T1 (el) 2017-03-15
KR20130121174A (ko) 2013-11-05
EP2670401A1 (en) 2013-12-11
SMT201500300B (it) 2016-01-08
AU2012212142A1 (en) 2013-08-15
KR101521861B1 (ko) 2015-05-21
CA2824092C (en) 2020-06-30
HRP20150946T1 (hr) 2015-10-09
EA023404B1 (ru) 2016-05-31
JP2014504646A (ja) 2014-02-24
PT2670401E (pt) 2015-10-12
CA2824092A1 (en) 2012-08-09
ES2543567T3 (es) 2015-08-20

Similar Documents

Publication Publication Date Title
BR112013019643A2 (pt) inibidores de alk, uso e composição farmacêutica compreendendo os mesmos
PH12020550552A1 (en) Inhibitors of hepatitis c virus
PH12017502141A1 (en) Compounds and their methods of use
PH12017501306A1 (en) Inhibitors of histone demethylases
MX336381B (es) Boronatos como inhibidores de arginasa.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
BR112012026641A2 (pt) compostos antivirais
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MY186599A (en) Substituted pyridopyrazines as novel syk inhibitors
IN2014CN04530A (pt)
MD20140124A2 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
CY1120133T1 (el) Πυριδαζινονες ως αναστολεις ενζυμου daao
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX363270B (es) Composiciones y metodos para inhibir la polimerasa viral.
GB201209587D0 (en) Therapeutic compounds
PH12015501038A1 (en) Inhibitors of iap
PH12015500399A1 (en) Azaindolines
TN2014000077A1 (en) Pyridazinone compounds and their use as daao inhibitors
SA515360233B1 (ar) مثبطات إنزيمات هستون ديميثيلاز

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.